US 11,052,126 B2
Method of treating diseases
Roni Mamluk, Mazkeret Batya (IL); and Sam L. Teichman, Oakland, CA (US)
Assigned to Chiasma, Inc., Needham, MA (US)
Filed by Chiasma, Inc., Needham, MA (US)
Filed on May 22, 2020, as Appl. No. 16/881,348.
Application 16/881,348 is a continuation of application No. 16/233,749, filed on Dec. 27, 2018, granted, now 10,695,397.
Application 16/233,749 is a continuation of application No. 15/014,634, filed on Feb. 3, 2016, granted, now 10,238,709, issued on Mar. 26, 2019.
Claims priority of provisional application 62/136,012, filed on Mar. 20, 2015.
Claims priority of provisional application 62/111,369, filed on Feb. 3, 2015.
Prior Publication US 2020/0390847 A1, Dec. 17, 2020
Int. Cl. A61K 38/31 (2006.01); A61P 5/06 (2006.01); A61K 38/08 (2019.01); A61K 9/48 (2006.01); A61K 9/00 (2006.01)
CPC A61K 38/08 (2013.01) [A61K 9/0053 (2013.01); A61K 9/4858 (2013.01); A61K 38/31 (2013.01); A61P 5/06 (2018.01)] 15 Claims
 
1. A method of treating acromegaly in a subject, the method comprising:
a) orally administering to the subject at least one dosage form comprising octreotide, wherein the subject is administered an H2-receptor antagonist or an antacid;
b) monitoring IGF-1 and clinical symptoms or biochemical and symptomatic response of the subject; and
c) if IGF-1 is not normal and clinical symptoms are not controlled or biochemical and symptomatic response is not maintained, then increasing the total dose of oral octreotide administered to the subject.